NASDAQ: ILMN

ILLUMINA, INC.

CIK 0001110803 · Health Care · SIC 3826 · Lab Analytical Instruments

Large Revenue $4.3B Assets $6.7B as of Aug 1, 2026

Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.

Sign up free

Want to see a complete report first? Today's free report (AAPL 10-Q) is open in full — no account needed.

10-Q Filed Jul 31, 2026 · Period ending Jun 28, 2026

Summary not yet generated.

8-K Filed Jul 30, 2026 · Period ending Jul 30, 2026

Summary not yet generated.

Partner

Trade ILMN commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed Jun 23, 2026 · Period ending Jun 16, 2026

Summary not yet generated.

8-K Filed May 26, 2026 · Period ending May 21, 2026

Summary not yet generated.

10-Q Filed May 4, 2026 · Period ending Mar 29, 2026

Summary not yet generated.

10-K Filed Feb 12, 2026 · Period ending Dec 28, 2025

Summary not yet generated.

10-K Filed Feb 12, 2025 · Period ending Dec 29, 2024

Summary not yet generated.

424B5 Filed Mar 4, 2021

Summary not yet generated.

424B3 Filed Feb 9, 2021

Summary not yet generated.

Latest financial statements

From 10-Q filed Jul 31, 2026 (period ending Jun 28, 2026). SEC XBRL (companyfacts) — not generated by the model.

SEC XBRL

Consolidated Statements of Operations (Unaudited)

Description Q2 ended Jun 28, 2026 Q1 ended Mar 29, 2026
Revenue:
Total revenue / net sales 1,159 1,091
Cost of revenue / cost of sales 389.0 370.0
Gross profit 770.0 721.0
Operating expenses:
Research and development 252.0 240.0
Selling, general and administrative 273.0 272.0
Total operating expenses 525.0 512.0
Operating income 245.0 209.0
Interest expense 24.0 24.0
Other income/(expense), net 15.0 (52.0)
Income before income taxes 260.0 157.0
Income tax expense/(benefit) 53.0 23.0
Net income 207.0
Basic earnings per share 1.37 0.88
Diluted earnings per share 1.35 0.87

Consolidated Balance Sheets (Unaudited)

Description Jun 28, 2026 Mar 29, 2026
Current assets:
Short-term investments 128.0 66.0
Accounts receivable, net 764.0 738.0
Inventories 629.0 611.0
Prepaid expenses and other current assets 273.0 234.0
Other current assets 1,040 1,089
Total current assets 2,834 2,738
Property, plant and equipment, net 745.0 755.0
Operating lease right-of-use assets, net 362.0 371.0
Finite-lived intangible assets, net 410.0 430.0
Goodwill 1,284 1,284
Deferred income taxes and other assets 439.0 458.0
Other long-term assets 576.0 523.0
TOTAL ASSETS 6,650 6,559
Current liabilities:
Accounts payable 230.0 218.0
Current portion of operating lease liabilities 82.0 80.0
Accrued liabilities 848.0 849.0
Income taxes payable 101.0 115.0
Deferred revenue, current 261.0 269.0
Other current liabilities 56.0 35.0
Total current liabilities 1,578 1,566
Operating lease liabilities 454.0 475.0
Deferred income taxes and other liabilities 289.0 352.0
Shareholders' equity:
Common stock 2.0 2.0
Capital in excess of stated value 7,933 7,862
Accumulated other comprehensive income (loss) 8.0 1.0
Retained earnings (deficit) (51.0) (258.0)
Treasury stock 5,054 4,931
Total shareholders' equity 2,838 2,676
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 6,650 6,559

Consolidated Statements of Cash Flows (Unaudited)

Description Six months ended Jun 28, 2026 Q1 ended Mar 29, 2026
Operating Activities:
Net cash from operating activities 490.0 289.0
Investing Activities:
Net cash from investing activities (488.0) (366.0)
Financing Activities:
Net cash from financing activities (380.0) (251.0)
Net increase/(decrease) in cash (378.0) (329.0)

Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗